Trials / Terminated
TerminatedNCT05272813
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MS-553 | MS-553 |
Timeline
- Start date
- 2022-04-28
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
- First posted
- 2022-03-09
- Last updated
- 2024-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05272813. Inclusion in this directory is not an endorsement.